SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

NCT03546582 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

86

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions

DRUG: Pembrolizumab
RADIATION: Stereotactic Body Radiation Therapy (SBRT)

Sponsor

RTOG Foundation, Inc.

Collaborators

[object Object]